Objective To observe the effect of continual rehabilitation on hemiplegic patients with stroke in the internal carotid artery system.Methods 60 hemiplegic cases with stroke in the internal carotid artery system were randomly divided into the continual rehabilitation group and early rehabilitationl group with 30 cases in each group.The patients in the continual rehabilitation group received continual rehabilitation besides the early rehabilitation in the rehabilitation unit or in the community with rehabilitation facities.The patients in the early rehabilitation group just received the early rehabilitation in the rehabilitation unit and then returned home with the guides from the doctors.Results The motor function and activities of daily living of the patients in the continual rehabilitation group were significantly better than that of the control group(P<0.01).Conclusion The continual rehabilitation can keep the continuity in rehabilitation,and is benefit to limb function and the activities of daily life of hemiplegic patients.

Objective:To develop an unnatural amino acid-labelled HiD-Hin47 fusion protein as a novel carrier.Methods:Twenty versions of the fusion protein were designed, each of which contained a different amino acid site replaced by an azide-bearing amino acid, N6-(2-azidoethoxy) (carbonyl)-L-Lysine (NAEK). These fusion proteins were constructed, expressed and purified, and the yield were evaluated by SDS-PAGE. Based on the highest protein yield, which was approximately 70% of the wild-type yield, the fusion protein with the unnatural amino acid in E677 site was selected. The pneumococcal polysaccharides of serotype 3 (F3) and serotype 6B (F6B) were coupled to the selected fusion protein through a "click" reaction. The conjugates were purified and compared in animal studies with other F3 and F6B conjugates that were coupled to CRM197, tetanus toxoid (TT) and HiD by conventional methods.Results:The immunogenicity of F3 conjugate using HiD-Hin47 as carrier (F3-HiD-Hin47) was slightly better than that of other F3 conjugates. F6B-HiD-Hin47 was significantly better than F6B-TT and F6B-HiD in terms of immunogenicity, but showed no significant difference with F6B-CRM197.Conclusions:NAEK-labelled HiD-Hin47 had the potential as a carrier for pneumococcal polysaccharide conjugate vaccine and was worthy of further study.